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The innate toxicity of copper can be exploited as an antimicrobial. In this issue of Chemistry & Biology Festa
and colleagues report the use of QBP, a prochelator form of the metal-chelate 8-hydroxyquinolone, which
allows for targeted copper-dependent microbial killing at sites of infection.Copper is vital to most life forms as a key
component of numerous enzymes and
other proteins. However, excess copper
is lethal and has led to the widespread
exploitation of this transition metal for its
antimicrobial properties. Indeed, copper
is used today in numerous settings
including healthcare, where its oldest
recorded medical use dates back to the
Smith Pyrus Egyptian text written around
4,500 years ago (Grass et al., 2011).
Recently, it has come to light that this
innate toxicity of copper is also a compo-
nent of our innate immune response.
Although the precise mechanism of how
copper contributes to these defenses is
unknown, there is increasing evidence
that the influx of copper into microbe-
containing phagosomes of macrophages
is a major factor (Hodgkinson and Petris,
2012). However, pathogens can sense
high copper levels within these com-
partments and trigger expression of cop-
per-resistance systems that allow their
survival (Osman and Cavet, 2011). In this
issue of Chemistry & Biology, Festa et al.
(2014) present a new approach for treat-
ing microbial infections that harnesses
copper mobilization in phagosomes in
combination with another key aspect of
the antimicrobial defenses there: the rapid
release of reactive oxygen species. This
association allows the prodrug QBP to
become activated to form antimicrobial
8-hydroxyquinolone (8HQ)-copper com-
plexes. Crucially, these complexes can
overcome microbial copper defenses to
result in pathogen killing (Figure 1).
The study focused on the fungal path-
ogen Cryptococcus neoformans. This
fungus can live in both plants and animals,
but, when inhaled by humans, can
disseminate from the lungs to the blood-
stream and cause life-threatening sys-temic disease. The brain is particularly
vulnerable to C. neoformans infections,
and there are approximately one million
cases of cryptococcal meningitis each
year, over 60% of which result in death
(Sabiiti and May, 2012). Treatment of
cryptococcal infections is notoriously
difficult, and new antifungal regimens
are urgently required.
The ability of the compound 8HQ to
form lipophilic complexes with metals
that translocate across cell membranes
and exert antimicrobial activity is well
documented. However, the toxicity of
8HQ-copper complexes is not path-
ogen-restricted, thus limiting its applica-
tion. To mitigate the ‘‘off-target effects,’’
Festa et al. (2014) exploited the use of
QBP, which is an inactive boronate-based
form of 8HQ and unable to bind copper
unless its boronic ester group is removed
by interaction with hydrogen peroxide or
peroxynitrite (Dickens and Franz, 2010;
Sikora et al., 2011). Because these reac-
tive oxygen species are a key feature of
phagocyte antimicrobial defenses, it was
hypothesized that QBP would be con-
verted to 8HQ by activatedmacrophages.
This was indeed demonstrated, and the
toxicity of QBP toward these cells is sub-
stantially reduced compared to that of
8HQ.
Crucially, the copper-binding ability of
8HQ causes a substantial potentiation of
copper toxicity toward C. neofomans.
Thus, by converting QBP to 8HQ by
treatment with hydrogen peroxide, Festa
et al. (2014) were able to conditionally
convert QBP to a copper-dependent anti-
fungal agent. Moreover, 8HQ-copper
complexes were found to be fungicidal
as a result ofC. neofomans over-accumu-
lating copper. As with other microbial
pathogens, C. neofomans possessesChemistry & Biology 21, August 14, 2014copper-resistance proteins. Such pro-
teins represent key microbial virulence
factors (Osman and Cavet, 2011). In
C. neoformans, they include small
cysteine-rich proteins known as metallo-
thioneins, and mutants lacking these
proteins are particularly vulnerable to
8HQ. Notably, treatment of activated
macrophages with QBP caused a sub-
stantial increase in their antifungal activ-
ity, despite an increase in C. neofomans
metallothionein gene expression. This
implies that the switch of QBP to 8HQ
by these phagocytes induces copper-
overloading sufficient to overcome
C. neofomans copper defenses and elicit
antifungal activity. Moreover, QBP was
used successfully to reduce the fungal
burden in the lungs of infected mice.
These findings clearly have clinical
implications in the treatment of
C. neofomans infections. However, the
use of QBP as a targeted antimicrobial is
likely to have applicability against a broad
spectrum of pathogens, because it is
based on two key aspects of phagocyte
antimicrobial defenses: the respiratory
burst and the mobilization of copper.
Indeed, Festa et al. (2014) demonstrated
the efficacy of 8HQ against other fungal
and bacterial pathogens. However, while
similar susceptibility to C. neoformans
was generally observed for other fungi
and Gram-positive bacteria, some
Gram-negative bacteria appeared less
susceptible, suggesting limitations in the
use of this treatment strategy for some
pathogens.
The study raises important questions.
First, what is the mechanism of toxicity
of the 8HQ-copper complexes? Because
8HQ toxicity is associated with increased
intracellular copper, pathogen killing
may result from copper displacing otherª2014 Elsevier Ltd All rights reserved 921
Figure 1. Conditional Activation of the Prodrug QBP Allows
Targeted Microbial Killing
QBP can only bind copper when converted to 8HQ via removal of its boronic
ester group by interaction with hydrogen peroxide (H2O2) or peroxynitrite
(ONOO). These reactive oxygen species are generated within macrophages
from superoxide (O2
), produced by the respiratory burst, and by its interac-
tion with nitric oxide (NO). The influx of copper into phagosomes occurs
in response to infection and is associated with increased expression of
the Ctr1 copper import protein and localization of the ATP7A copper pump
to phagosome-associated vesicles, with Atox1 acting to shuttle copper to
ATP7A. The resultant lipophilic 8HQ copper complexes overcome microbial
copper defenses, resulting in pathogen (C. neo) killing.
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sites of proteins, particularly
exposed iron-sulfur clusters,
because these represent a
primary target for inhibition
by copper (Macomber and
Imlay, 2009). Alternatively,
liberated intracellular 8HQ
may bind other metals and
inhibit metalloenzymes, and/
or intact 8HQ-copper com-
plexes may act directly, for
example by inhibiting the pro-
teasome as has previously
been observed (Zhai et al.,
2010). Second, what is the
source of copper for the for-
mation of the 8HQ-copper
complexes in phagocytes?
This may be derived from
the mobilization of intracel-
lular copper stores and/or
extracellular recruitment, for
example from ceruloplasmin,
which is the major copper-
containing protein in plasma.
Third, does QBP activation
occur in professional phago-
cytes other than macro-
phages, such as dendriticcells, microglia, and neutrophils? If so,
this may further broaden the spectrum of
susceptible diseases.
In conclusion, Festa et al. (2014) pre-
sent exciting work that lays the founda-
tion for the utilization of molecules that922 Chemistry & Biology 21, August 14, 2014specifically target sites of phagocytosis
and thereby minimize cytotoxicity to the
host. The requirement for both copper
and reactive oxygen species for the
activation of the prodrug QBP to 8HQ
endows it with a unique conditionallyª2014 Elsevier Ltd All rights reservedactivated antimicrobial activ-
ity. 8HQ has potentiated effi-
cacy against a broad spec-
trum of microbial pathogens
and appears particularly well
suited for the treatment of
recalcitrant fungal infections
such as cryptococcosis.REFERENCES
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